Table 5.
Mean Annual Costs (EUR) of Primary Care Patients (Discontinuation Versus Persistence) in the NPH Group.
| Variables | NPH discontinuation costs prior ID | NPH costs post ID | NPH persistence costs prior ID | NPH costs post ID | Cost difference (post vs prior ID): discontinuation vs persistence |
|---|---|---|---|---|---|
| N | 146 | 146 | 1342 | 1342 | |
| Total treatment costs | 724 (460) | 1158 (638) | 686 (444) | 1160 (645) | 21 (52); P = .6781a |
| Diabetes-related prescription costs | 455 (395) | 890 (588) | 451 (393) | 908 (566) | −14 (44); P = .7570 |
| Insulin, oral/injectable antidiabetics | 403 (376) | 627 (469) | 380 (351) | 647 (430) | — |
| Consumables | 52 (93) | 263 (276) | 72 (145) | 261 (293) | — |
| Treatment of hypoglycemia (glucagon i.m., glucose i.v.) | 0.0 (0.0) | 0.2 (2.7) | 0.0 (0.9) | 0.1 (2.3) | — |
| Other medical services | 269 (219) | 268 (303) | 235 (212) | 252 (235) | −4 (20); P = .8658 |
Data are means (SD). Patients with and without discontinuation were propensity score matched for age, sex, diabetes duration, diabetologist care, disease management program participation, and Charlson Comorbidity Index; cost differences were further adjusted for baseline costs and HbA1c. ID, index date of starting NPH basal insulin therapy. Cost difference (last column): positive values represent savings; negative values are excess expenditure.
a
P values: difference (discontinuation vs persistence) of costs differences (post/prior ID).